President of Kronos Bio Picks Up 36% More Stock
President of Kronos Bio Picks Up 36% More Stock
Kronos Bio, Inc. (NASDAQ:KRON) shareholders (or potential shareholders) will be happy to see that the President, Norbert Bischofberger, recently bought a whopping US$3.1m worth of stock, at a price of US$1.04. Aside from being a solid chunk in its own right, the deft move also saw their holding increase by some 36%.
Kronos Bio, Inc.（納斯達克：KRON）的股東（或潛在股東）將很高興地看到公司總裁Norbert Bischofberger最近以1.04美元的價格大手筆買入了價值3.1美元的股票。除了本身是堅實的一筆之外，這一巧妙的交易還促使他們的持股量增加了約36%。
Kronos Bio Insider Transactions Over The Last Year
Kronos Bio近年來的內部交易
In fact, the recent purchase by Norbert Bischofberger was the biggest purchase of Kronos Bio shares made by an insider individual in the last twelve months, according to our records. That means that even when the share price was higher than US$1.08 (the recent price), an insider wanted to purchase shares. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Norbert Bischofberger was the only individual insider to buy during the last year.
實際上，根據我們的記錄，Norbert Bischofberger最近的購買是最近12個月內製定由內部個人採購Kronos Bio股票的最大交易。這意味着即使股價高於1.08美元（最近的價格），內部人士仍想購買股票。他們的觀點可能已經改變，但至少表明他們在當時感到樂觀。對於我們而言，考慮內部人士購買股票的價格非常重要。通常情況下，當內部人士以高於當前價格的價格購買股票時，我們對股票的態度更加積極，因爲這表明他們認爲該股票具有較高的價值，即使價格更高。Norbert Bischofberger是過去一年內唯一購買的內部個人內部人士。
Norbert Bischofberger purchased 4.74m shares over the year. The average price per share was US$0.97. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Norbert Bischofberger在過去一年中購買了474萬股。每股平均價格爲0.97美元。您可以在下面看到對上市公司和個人的內部交易（可視化呈現）過去12個月的視覺描述。如果您單擊圖表，則可以查看所有單獨的交易，包括股票價格、個人和日期！
There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).
內部人士正在購買的股票是無數的。如果您喜歡投資於較少知名公司，您可以查看此免費的公司列表(提示：內部人士一直在購買它們)。
Insider Ownership
內部人員持股情況
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. It appears that Kronos Bio insiders own 26% of the company, worth about US$17m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
我喜歡查看內部人士在公司擁有多少股份，以幫助了解他們與內部人士的一致性程度。我們通常希望看到相當高水平的內部所有權。 Kronos Bio內部人士持有公司的26％，價值約17百萬美元。雖然這不是非常突出的內部所有權水平，但足以表明管理層和較小的股東之間存在一些共識。
What Might The Insider Transactions At Kronos Bio Tell Us?
Kronos Bio的內部交易可能向我們傳達什麼信息？
The recent insider purchase is heartening. We also take confidence from the longer term picture of insider transactions. But we don't feel the same about the fact the company is making losses. Given that insiders also own a fair bit of Kronos Bio we think they are probably pretty confident of a bright future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. In terms of investment risks, we've identified 4 warning signs with Kronos Bio and understanding them should be part of your investment process.
最近的內部人士購買是令人振奮的。我們還從內部交易的長期圖像中獲得信心。但是，我們對該公司虧損的事實持不同意見。考慮到內部人士也擁有Kronos Bio的相當一部分份額，我們認爲他們可能非常有信心迎來輝煌的明天。因此，雖然了解內部人士在購買或出售方面所做的事情很有幫助，但了解一個特定公司面臨的風險也很有幫助。就投資風險而言，我們已經確定了Kronos Bio的4個警示信號，了解它們應該是您投資過程中的一部分。
Of course Kronos Bio may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
當然，Kronos Bio可能不是最好的股票。因此，您可能希望查看這個免費收藏的優質公司。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言，內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置，但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者，發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論，只使用公正的方法論，我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議，也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意，我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。
譯文內容由第三人軟體翻譯。